Dynavox Group AB (publ) DYVOX.ST
Nasdaq Stockholm · Healthcare · Medical Instruments & Supplies
70.80 SEK
−1.8%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for Dynavox Group
| SEK million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 1,216 | 1,613 | 1,972 | 2,467 |
| EBITDA | 199 | 321 | 425 | 476 |
| Net income | 49 | 104 | 146 | 166 |
| Balance sheet | ||||
| Equity | 211 | 298 | 454 | 602 |
| Total debt | 628 | 773 | 791 | 1,104 |
| Cash | 107 | 161 | 134 | 195 |
| Net debt | 522 | 612 | 657 | 909 |
| Ratios and per share | ||||
| EBITDA margin | 16.3% | 19.9% | 21.6% | 19.3% |
| Profit margin | 4.0% | 6.5% | 7.4% | 6.7% |
| Return on equity | 23.1% | 35.0% | 32.1% | 27.5% |
| Earnings/share (SEK) | 0.46 | 0.99 | 1.39 | 1.57 |
| Book value/share (SEK) | 2.01 | 2.84 | 4.33 | 5.71 |
| Shares outstanding (M) | 105 | 105 | 105 | 106 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | 45.1 |
| P/B | 12.4 |
| EV / EBITDA | 17.6 |
| Net debt / EBITDA | 1.9 |
| Return on equity | 27.5% |
| Profit margin | 6.7% |
| Beta 1Y | 1.23 |
| Revenue growth 1Y | +25.1% |
| Revenue CAGR 3Y | +26.6% |
| Earnings/share CAGR 3Y | +50.2% |
| ROE avg. 3Y | 31.5% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (SEK)
| 2026 | 0.50 |
Not investment advice. Figures may contain errors from the data source.